Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
暂无分享，去创建一个
F. Montemurro | G. Missale | L. Carbognin | G. Bisagni | A. Frassoldati | E. Fiorio | E. Cretella | N. Campanini | B. Pellegrino | A. Musolino | Renata Todeschini | A. Zambelli | C. Zamagni | E. M. Silini | Chiara Tommasi | Olga Serra | Emilio Bria | L. Gianni | Stefania Gori | G. Maglietta | M. Ambroggi | Chiara Casarini | Antonella Mura | Michele Tognetto